Statements (162)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
gptkb:robot gptkb:drug |
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Acel_Rx_Pharmaceuticals
|
| gptkbp:accessories |
various add-ons
|
| gptkbp:activities |
NMDA receptor antagonist
serotonin reuptake inhibitor opioid receptor agonist |
| gptkbp:analysis |
included
|
| gptkbp:application |
warehouse management
|
| gptkbp:appointed_by |
oral route
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:battery_life |
8 hours
|
| gptkbp:capacity |
500 kg
|
| gptkbp:certification |
gptkb:standard
|
| gptkbp:character_customization |
gptkb:battle
|
| gptkbp:class |
analgesics
opioids |
| gptkbp:clinical_trial |
gptkb:Europe
gptkb:United_States gptkb:Native_American_tribe Phase 2 chronic pain ongoing studies post-operative pain conducted for efficacy cancer pain Arixa Pharmaceuticals |
| gptkbp:collaborations |
academic institutions
healthcare providers clinical research organizations works with other robots |
| gptkbp:color |
gptkb:blue
|
| gptkbp:communication |
gptkb:Wi-Fi
|
| gptkbp:community |
active
|
| gptkbp:contains |
active pharmaceutical ingredients
|
| gptkbp:contraindication |
acute or severe asthma
severe respiratory depression |
| gptkbp:controls |
gptkb:battle
|
| gptkbp:deployment |
indoor and outdoor
|
| gptkbp:designed_by |
ARX Corporation
|
| gptkbp:developed_by |
Arixa Pharmaceuticals
|
| gptkbp:dosage_form |
gptkb:tablet
tablets 30 mg 60 mg |
| gptkbp:duration |
as prescribed by physician
|
| gptkbp:environmental_impact |
water resistant
|
| gptkbp:features |
AI navigation system
|
| gptkbp:feedback |
real-time monitoring
integrated |
| gptkbp:form |
oral tablet
|
| gptkbp:formulation |
gptkb:tablet
oral extended-release |
| gptkbp:frequency |
twice daily
|
| gptkbp:fuel_capacity |
high
|
| gptkbp:height |
1.5 m
|
| https://www.w3.org/2000/01/rdf-schema#label |
ARX-03
|
| gptkbp:ingredients |
gptkb:quetiapine
gptkb:acetaminophen dextromethorphan hydrocodone |
| gptkbp:installation |
offered
|
| gptkbp:interacts_with |
CNS depressants
CY P2 D6 inhibitors CY P3 A4 inhibitors CY P450 inhibitors CY P2 D6 substrates CY P3 A4 substrates may enhance sedative effects may increase risk of overdose |
| gptkbp:invention |
patented
Arixa Pharmaceuticals |
| gptkbp:is_capable_of |
object recognition
|
| gptkbp:is_compatible_with |
various industrial equipment
|
| gptkbp:is_used_for |
industrial automation
chronic pain moderate pain management |
| gptkbp:launch_date |
gptkb:2018
|
| gptkbp:maintenance |
6 months
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
ARX Corporation
Arixa Pharmaceuticals |
| gptkbp:market |
gptkb:2021
investigational |
| gptkbp:market_segment |
manufacturing
|
| gptkbp:marketed_as |
gptkb:skincare_product
|
| gptkbp:operating_system |
gptkb:operating_system
|
| gptkbp:partnerships |
various tech companies
|
| gptkbp:pharmacokinetics |
metabolized in liver
half-life of 4-6 hours pain relief effect |
| gptkbp:population |
risk of addiction
avoid alcohol take with food chronic pain patients do not exceed prescribed dose |
| gptkbp:power_output |
electric
|
| gptkbp:price |
$50,000
|
| gptkbp:produced_by |
limited
under investigation |
| gptkbp:provides_information_on |
machine learning algorithms
follow physician's instructions recommended for moderate pain |
| gptkbp:regulatory_compliance |
approved
not approved |
| gptkbp:related_model |
gptkb:ARX-03
|
| gptkbp:research |
improved quality of life
clinical research patient satisfaction pain reduction pharmacological study efficacy study safety study reduced opioid use enhanced functional ability |
| gptkbp:research_and_development |
ongoing
|
| gptkbp:research_focus |
chronic pain management
pain management strategies chronic pain treatment opioid safety |
| gptkbp:safety_features |
generally well tolerated
emergency stop button monitored in clinical settings |
| gptkbp:sensor |
LIDAR
|
| gptkbp:side_effect |
gptkb:software
dizziness nausea allergic reactions withdrawal symptoms drowsiness constipation dry mouth respiratory depression |
| gptkbp:speed |
2 m/s
|
| gptkbp:storage |
cloud-based
room temperature |
| gptkbp:succeeded_by |
high
|
| gptkbp:supports |
24/7 customer support
|
| gptkbp:target_audience |
businesses
adults elderly patients with chronic pain |
| gptkbp:targets |
fibromyalgia
neuropathic pain |
| gptkbp:training |
gptkb:battle
gptkb:stock_market_index |
| gptkbp:treatment |
enhanced quality of life
improved pain management |
| gptkbp:type |
autonomous robot
|
| gptkbp:type_of_care |
important for effectiveness
|
| gptkbp:updates |
planned
regularly provided |
| gptkbp:user_interface |
touchscreen
|
| gptkbp:user_manual |
provided
|
| gptkbp:user_reviews |
positive
|
| gptkbp:warranty |
2 years
|
| gptkbp:weight |
150 kg
|
| gptkbp:year_created |
gptkb:2021
|